臺灣博碩士論文加值系統

急性前葡萄膜炎是人類最常見的葡萄膜炎型式。此眼疾會明顯導致視力障礙而且其確切的致病機制尚未有定論。本研究在實驗性自體免疫前葡萄膜炎的分子醫學機制研究中，成功地建立了路易斯大鼠的活體動物模式。因而在此實驗中，我們探究了實驗性自體免疫前葡萄膜炎中能將特定白血球分群細胞吸引到眼部發炎部位的一種趨化激素 lymphotactin 及其受體的表現。我們觀察到前房水中白血球的數量隨著虹膜與睫狀體的發炎狀態惡化而增加而且因 lymphotactin 及其受體於疾病進程的虹膜與睫狀體中即有此趨化激素基因核酸序列的相關表現；因而在其前房水中lymphotactin 蛋白質表現量亦於發炎狀態較高峯時有較高濃度產生。此外；本研究亦證實核轉錄因子抑制劑 PDTC ( Pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor ) 可於發炎狀態較高峯時顯著抑制前房水中lymphotactin 蛋白質表現量。進而我們探究了流式細胞儀的分析結果顯示具有 lymphotactin 抗體呈色的CD8 + 毒殺型Ｔ細胞數量亦隨著發炎狀態惡化而增加；而且免疫組織化學染色法也呈現出 lymphotactin 表現於虹膜與睫狀體中浸潤的炎症細胞。總而言之，毒殺型Ｔ細胞所產生的 lymphotactin 是實驗性自體免疫前葡萄膜炎致病機制的重要角色而且參與疾病進程的發炎狀態中特定炎症細胞進入到虹膜與睫狀體的徵集。因此實驗性自體免疫前葡萄膜炎的虹膜與睫狀體之趨化激素 lymphotactin 及其受體的調節研究分析應有助於呈現疾病進程的機制進而期望能發展有效的生化檢驗方法並對阻斷此致病機制來緩解與治療人類的急性前葡萄膜炎的目標有所貢獻。

Acute anterior uveitis (AAU) is the most common form of uveitis in humans and the exact mechanism of AAU has yet to be determined. We have successfully created an animal model of Experimental Autoimmune Anterior Uveitis (EAAU) in Lewis rat. In this experiment, we studied the expression of lymphotactin – a chemokine which attracts lymphocytes to inflammation sites in the EAAU. We observed that the leukocytes of aqueous humor increased with the severity of inflammation of iris/ciliary body. There were specific lymphotactin and its receptor messenger RNA expressions in iris/cilicary body in EAAU. The expression of lymphotactin receptor in iris/ciliary body correlated with that of lymphotactin. Furthermore, the lymphotactin protein levels of aqueous humor also correlated with the disease process. Pyrrolidine dithiocarbamate (PDTC), a nuclear factor kappa B inhibitor, markedly inhibited the expression of lymphotactin protein in the aqueous humor. Immunohistochemical staining revealed that lymphotactin was expressed on infiltrated inflammatory cells of iris/ciliary body. Flow cytometry analysis revealed that there was increasing number of CD8 + cytotoxic T cells with positive lymphotactin staining with the severity degree of inflammation. In conclusion, lymphotactin played an important role in the pathogenesis of EAAU and could attract more inflammatory cells to the iris/ciliary body.

目錄-----------------------------------------第1頁
亞洲大學碩士論文授權書--------------第2頁
口試委員會審定書-----------------------第3頁
縮寫-----------------------------------------第4頁
摘要-----------------------------------------第5頁
Abstract------------------------------------第6頁
Introduction-------------------------------第7頁
Methods -----------------------------------第11頁
Results -------------------------------------第17頁
Discussions--------------------------------第21頁
Tables illustrations/Figures legends--第28頁
References---------------------------------第43頁
誌謝-----------------------------------------第47頁

References

[1] Nussenblatt RB, Whitcup SM. Uveitis: Fundamentals and Clinical Practice. 3rd ed. Philadelphia: Mosby/Elsevier Science; 2004: 273-286.
[2] Broekhuyse RM, Kuhlman ED, Winkens HJ, Van Vugt AHM. Experimental autoimmune anterior uveitis (EAAU), a new form of experimental uveitis, I: induction by a detergent-insoluble, intrinsic protein fraction of the retinal pigmental epithelium. Exp. Eye Res. 1991; 52:465–474.
[3] Broekhuyse RM, Kuhlman ED, Winkens HJ. Experimental autoimmune anterior uveitis (EAAU). II. Dose-dependent induction and adoptive transfer using a melanin-bound antigen of the retinal pigment epithelium. Exp. Eye Res. 1992; 55:401–411.
[4] Broekhuyse RM, Kuhlman ED. Experimental autoimmune anterior uveitis. The preparation of uveitogenic ocular melanin. Invest. Ophthalmol. Vis. Sci. 1993; 34:698-700.
[5] Broekhuyse RM, Winkens HJ, Kuhlmann ED. Intraperitoneally injected melanin is highly uveitogenic. Exp. Eye Res. 1996; 62:199–200.
[6] Broekhuyse RM, Huitinga I, Kuhlman ED, Van Rooijen N, Winkens HJ. Differential effect of macrophage depletion on two forms of experimental uveitis evoked by pigment epithelial membrane protein (EAPU), and by melanin-protein (EMIU). Exp. Eye Res. 1997; 65:841–848.
[7] Chan CC, Hikita N, Dastgheib K, Whitcup SM, Gery I, Nussenblatt RB. Experimental melanin-protein-induced uveitis in the Lewis rat. Immunopathologic processes. Ophthalmology 1994; 101:1275-1280.
[8] Bora NS, Kim MC, Kabeer NH, Simpson SC, Tandhasetti MT, Cirrito TP, Kaplan AD, Kaplan HJ. Experimental autoimmune anterior uveitis. Induction with melanin-associated antigen from the iris and ciliary body. Invest. Ophthalmol. Vis. Sci. 1995; 36:1056-1066.
[9] Kim MC, Kabeer NH, Tandhasetti MT, Kaplan HJ, Bora NS. Immunohistochemical studies on melanin associated antigen (MAA) induced experimental autoimmune anterior uveitis (EAAU). Curr. Eye Res. 1995; 14:703-710.
[10] Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multi-step paradigm. Cell 1994; 76:301-314.
[11] Rollins BJ. Chemokines. Blood 1997; 90:909-928.
[12] Verma MJ, Lloyd A, Rager H. Chemokines in acute anterior uveitis. Curr. Eye Res. 1997; 16:1202-1208.
[13] Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392:565-568.
[14] Yoshida T, Imai T, Kakizaki M, Nishimura M, Takagi S, Yoshie O. Identification of single C motif-1/lymphotactin receptor XCR1. J. Biol. Chem. 1998; 273:16551–16554.
[15] Yoshida T, Izawa D, Nakayama T, Nakahara K, Kakizaki M, Imai T. Molecular cloning of mXCR1, the murine SCM-1/lymphotactin receptor. FEBS Lett. 1999; 458:37–40.
[16] Shan L, Qiao X, Oldham E, Catron D, Kaminski H, Lundell D, Zlotnik A, Gustafson E, Hedrick JA. Identification of viral macrophage inflammatory protein (vMIP)-II as a ligand for GPR5/XCR1. Biochem. Biophys. Res. Commun. 2000; 268:938-941.
[17] Dorner BG, Scheffold A, Rolph MS, Kaufmann SH, Radbruch A. MIP-1, MIP-1, RANTES, and ATAC/lymphotactin function together with IFN-γas type 1 cytokines. Proc. Natl. Acad. Sci. U.S.A. 2002; 99:6181–6186.
[18] Muller S, Dorner B, Korthauer U, Mages HW, D’Apuzzo M, Senger G. Cloning of ATAC, an activation-induced, chemokine-related molecule exclusively expressed in CD8+ T lymphocytes. Eur. J. Immunol. 1995; 25:1744–1748.
[19] Kennedy J, Kelner GS, Kleyensteuber S, Schall TJ, Weiss MC, Yssel H. Molecular cloning and functional characterization of human lymphotactin. J. Immunol. 1995; 155:203–209.
[20] Dorner B, Muller S, Entschladen F, Schroder JM, Franke P, Kraft R. Purification, structural analysis, and function of natural ATAC, a cytokine secreted by CD8+ T cells. J. Biol. Chem. 1997; 272:8817–8823.
[21] Hedrick JA, Zlotnik A. Lymphotactin. Clin. Immunol. Immunopathol. 1998; 87:218–222.
[22] Giancarlo B, Silvano S, Albert Z, Mantovani A, Allavena P. Migratory response of human natural killer cells to lymphotactin. Eur. J. Immunol. 1996; 26:3238–3241.
[23] Hedrick JA, Saylor V, Figueroa D, Mizoue L, Xu Y, Menon S. Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo. J. Immunol. 1997; 158:1533–1540.
[24] Kelner GS, Kennedy J, Bacon KB, Kleyensteuber S, Largaespada DA, Jenkins NA. Lymphotactin: a cytokine that represents a new class of chemokine. Science 1994; 266:1395–1399.
[25] Yoshida T, Imai T, Kakizaki M, Nishimura M, Yoshie O. Molecular cloning of a novel C or gamma type chemokine, SCM-1. FEBS Lett. 1995; 360:155–159.
[26] Adamus G, Manczak M, Machnicki M. Expression of CC chemokines and their receptors in the eye in autoimmune anterior uveitis associated with EAE. Invest. Ophthalmol. Vis. Sci. 2001; 42:2894-2903.
[27] Fang IM, Yang CH, Lin CP, Yang CM, Chen MS. Expression of chemokine and receptors in Lewis rats with experimental autoimmune anterior uveitis. Exp. Eye Res. 2004; 78:1043–1055.
[28] Wang JD, Nonomura N, Takahara S, Li BS, Azuma H, Ichimaru N. Lymphotactin: a key regulator of lymphocyte trafficking during acute graft rejection. Immunology 1998; 95:56–61.
[29] Segerer S, Cui Y, Eitner F, Goodpaster T, Hudkins KL, Mack M. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am. J. Kidney Dis. 2001; 37:518–531.
[30] Bradley LM, Asensio VC, Schioetz LK, Harbertson J, Krahl T, Patstone G. Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J. Immunol. 1999; 162:2511–2520.
[31] Blaschke S, Middel P, Dorner BG, Blaschke V, Hummel KM, Kroczek RA, Reich K, Benoehr P, Koziolek M, Muller GA. Expression of activation-induced, T cell–derived, and chemokine-related cytokine / lymphotactin and its functional role in Rheumatoid Arthritis, Arthritis Rheum. 2003; 48:1858–1872.
[32] Natori YU, Ou ZL, Yamamoto SY, Natori Y. Expression of lymphotactin mRNA in experimental crescentic glomerulonephritis. Clin. Exp. Immunol. 1998; 113:265–268.
[33] Middel P, Thelen P, Blaschke S, Polzien F, Reich K, Blaschke V. Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn’s disease. Am. J. Pathol. 2001; 159:1751–1761.
[34] Boismenu R, Feng L, Xia YY, Chang JC, Havran WL. Chemokine expression by intraepithelial γ / θ T cells: implications for the recruitment of inflammatory cells to damaged epithelia. J. Immunol. 1996; 157:985–992.
[35] Zhang W, He L, Yuan Z, Xie Z, Wang J, Hamada H. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Hum. Gene Ther. 1999; 10:1151–1161.
[36] Yu HG, Chung H, Lee WJ. Apoptosis of CD4 + T cells occurs in experimental autoimmune anterior uveitis (EAAU). Clin. Exp. Immunol. 1999; 118:357-363.
[37] Yu HG, Lee DS, Seo JM, Ahn JK, Yu YS, Lee WJ, Chung H. The number of CD8 + T cells and NKT cells increases in the aqueous humor of patients with Behçet’s uveitis. Clin. Exp. Immunol. 2004; 137:437–443.
[38] Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor-B activation in intact cells. J. Exp. Med. 1992; 175:1181-1194.
[39] Liu SF, Ye X, Malik AB. Pyrrolidine dithiocarbamate prevents I-B degradation and reduces microvascular injury induced by lipopolysaccharide in multiple organs. Mol. Pharmacol. 1999; 55:658-667.
[40] Frantz B, Nordby EC, Bren G, Steffan N, Paya CV, Kincaid RL, Tocci MJ, O'Keefe SJ, O'Neill EA. Calcineurin acts in synergy with PMA to inactivate I-B/MAD3, an inhibitor of NF-B. EMBO J. 1994; 13:861 -870.
[41] Baeuerle PA, Henkel T. Function and activation of NF-B in the immune system. Annu. Rev. Immunol. 1994; 12:141-179.
[42] Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-B, a ubiquitous transcription factor in the initiation of diseases. Clin. Chem. 1999; 45:7-17.
[43] Tak PP, Firestein GS. NF-B: a key role in inflammatory diseases. J. Clin. Invest. 2001; 107:7-11.
[44] Yoshida T, Imai T, Takagi S, Nishimura M, Ishikawa I, Yaoi T, Yoshie O. Structure and expression of two highly related genes encoding SCM-1/human lymphotactin. FEBS Lett. 1996; 395:82–88.
[45] Rumsaeng V, Vliagoftis H, Oh CK, Metcalfe DD. Lymphotactin gene expression in mast cells following Fc receptor I aggregation: modulation by TGF-, IL-4, dexamethasone, and cyclosporin A. J. Immunol. 1997; 158:1353–1360.
[46] Yoshida T, Ishikawa I, Ono Y, Imai T, Suzuki R, Yoshie O, An activation-responsive element in single c motif-1 / Lymphotactin promoter is a site of constitutive and inducible DNA-Protein interactions involving nuclear factor of activated T cell. J. Immunol. 1999; 163:3295-3303.
[47] Dorner BG, Steinbach S, Huser MB, Kroczek RA, Scheffold A. Single-cell analysis of the murine chemokines MIP-1, MIP-1, RANTES, and ATAC / lymphotactin by flow cytometry. J. Immunol. Methods 2003; 274:83–91.
[48] Maghazaciu AA, Skalhegg BS, Rolstad B, Alaoukaty A. Interferon – γ inducible protein-10 and lymphotactin induce the chemotaxis and mobilization of intracellular calcium in natural killer cells through pertussis toxin sensitive and insensitive heterotrimeric G-proteins. FASEB J. 1997; 11:765-774.
[49] Fields TA, Casey PJ. Signalling functions and biochemical properties of pertussis toxin-resistant G-proteins. Biochem. J. 1997; 321:561-571.
[50] Jabs DA, Rosenbaum JT, Foster CS. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendation of an expert panel. Am. J. Ophthalmol. 2000; 130:492-513.
[51] Murphy CC, Greiner K, Duncan L, Forrester JV, Dick AD. Cyclosporine vs Tacrolimus Therapy for Posterior and Intermediate Uveitis. Arch. Ophthalmol. 2005; 123:634-641.
[52] Yang WM, Inouye CJ, Seto E. Cyclophilin A and FKBPl2 interact with YY1 and alter its transcriptional activity. J. Biol. Chem. 1995; 270:15187-15193.